eli lilly glp 1 pipeline Beyond the Needle: Lilly's Orforglipron and the Small Molecule GLP-1 Revolution Strong pipeline to help Eli

Lets work together to find relief and get you comfortable again

Non-inferiority of BYDUREON 2 mg QW to pioglitazone 30-45 mg/day (mean dose 40 mg/day at study endpoint) in reducing HbA1c after 26 weeks of treatment was not demonstrated (the mean change from baseline in HbA1c after 26 weeks was -1.6% with BYDUREON and -1.7% with pioglitazone)

Implications for employers: This study provides evidence that pharmaceutical manufacturers could make substantial profits selling these drugs at much lower costs in the US

What if I forget to take my medication

A note on why the concentration choice matters beyond convenience: a higher-concentration build (10 mg/mL) keeps every draw comfortably inside one barrel across the whole ladder, but leaves less margin for a small measurement slip, since each unit carries more drug